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Abstract
Introduction. The colorectal cancer (CRC) is one of the most frequent cancer in Poland and worldwide. This 
disease is characterized by distinct genetic alterations. p73 belongs to the p53 gene family; however, its role in 
the pathogenesis of CRC has not been completely understood. p73 gene encodes several mRNA variants and 
protein isoforms with its longest and fully functional p73a (mRNA) and TAp73a (protein) isoform. The aim 
of the study was to investigate p73 gene expression at the mRNA (p73a) and protein (TAp73a) levels in CRC.
Material and methods. Small sections of the CRC tumor tissue and macroscopically unchanged colon mucosa 
and submucosa from the dissection margin were collected from 23 patients diagnosed with CRC. p73 mRNA 
levels were measured by Real-time PCR (QPCR) method and the expression level of TAp73a protein was as-
sessed by Western blotting (WB) and immunohistochemical (IHC) staining.
Results. We found a 37% decrease in the level of p73a mRNA in neoplastically changed (tumor) compared 
with unchanged normal colon tissue from the surgical margin (p = 0.041). No correlations were found between 
mRNA levels in cancer tissue and clinical-pathological parameters. 
The semi-quantification of TAp73a protein revealed lower and higher TAp73a protein contents in 11/23 and 
12/23 of tumor samples, respectively, when compared with the median value of TAp73a protein in normal colon 
tissue (p = 0.61). The level of TAp73a protein level was 5 times lower in poorly differentiated cancer cells (G3) 
in comparison to moderately differentiated ones (G2; p = 0.02). No statistically significant correlations were 
observed between the level of the TAp73a protein and clinical-pathological patients’ characteristics. 
The IHC analysis of TAp73a protein presence in CRC samples showed decreased immunoreactivity when com-
pared with matched sections of the unchanged colon wall in 4/9 patients, similar intensity of the IHC reaction 
in 4/9 patients and increased immunoreactivity in 1/9 patients. The TAp73a protein was localized mainly in the 
cytoplasm of the cancer cells. No statistically significant correlations between IHC results and clinical-patho-
logical features of the patients were found.
Conclusions. The obtained results suggest that the p73 gene may play a role as a tumor suppressor in the CRC 
progression. (Folia Histochemica et Cytobiologica 2016, Vol. 54, No. 3, 166–170)
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Colorectal cancer (CRC), a multifactorial disease 
caused by genetic, lifestyle and environmental factors, 
belongs to the most common malignancies in the world. 
Although nearly 90% of patients may be successfully 
cured by surgery at the early stage, CRC is frequently 
diagnosed at the late stage, i.e. Dukes’ C and D, when 
the prognosis is poor [1, 2]. Similarly as in other can-
cer types, CRC development is associated with dys-
regulation of some important intracellular signaling 
pathways such as p53 or Wnt/b-catenin [3]. Tumor 
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protein TP73 along with p63, belongs to the p53 gene 
family and can induce cell cycle arrest as well as apop-
tosis via the activation of p53-responsive genes [4]. 
On the contrary, the over-expression of p73 gene was 
observed in several types of neoplasms, suggesting the 
oncogenic role of p73 gene in cancer development 
and progression [5]. The findings of either suppressor 
or oncogenic role of TP73 protein in carcinogenesis 
may be associated with different functions of several 
isoforms of the TP73 protein [4–6]. p73a mRNA vari-
ant encodes the longest protein isoform (69.6 kDa, 
636aa) characterized by the occurrence of three do-
mains: transactivation (TA), DNA-binding and pro-
line-rich ones. Other p73 mRNA variants (aTAp73 
and ∆Np73) encode smaller or truncated proteins 
which lack at least one domain (i.e. aTAp73 does 
not contain TA domain) [7]. Although there are nu-
merous studies related to the p53 status in CRC, the 
reports on the expression of p73 gene and protein in 
this type of cancer are scarce and unequivocal [8–10]. 
In CRC the association between TP73 protein level 
and cancer progression was barely studied and the 
results were opposite [11]. Therefore, we decided 
to assess the expression of the TP73 gene in paired 
tumor-surgical margin specimens of CRC patients at 
the mRNA and protein levels.
The retrospective study was approved by the local 
bioethics committee, and informed, written consent 
regarding the use of tissue was obtained before 
surgery from all CRC patients. The specimens were 
obtained from two surgical clinics from 2011 to 2014 
(Department of Oncological Surgery, Warmia and 
Mazury Oncological Center, Olsztyn and Department 
of General, Endocrine, and Transplant Surgery, Med-
ical University of Gdansk, Gdansk, Poland). Clinical 
and demographic data were collected at the time of 
enrollment.
The samples were obtained from 23 CRC patients: 
17 females and 6 males; the median age was 70 years 
(range: 54–89 years, mean age: 69 years).The tumor 
location was: rectum (N = 8), sigmoid/descending 
colon (N = 4), transverse colon/splenic flexure 
(N = 4) and cecum/ascending colon (N = 7). The sizes 
of tumor were: < 3 cm (N = 1), 3–5 cm (N = 12), 
> 5 cm (N = 10). According to the UICC/AJCC 
classification applicable to 22 patients the following 
staging was obtained: stage I (N = 1), stage II (N = 7), 
stage III (N = 11), stage IV (N = 3). The histological 
G grading data was obtained for 21 patients: G2 (mod-
erately differentiated cells; N = 18) and G3 (poorly 
differentiated cells, N = 3). 
The collection of neoplastically changed (tumor) 
and normal colon tissue samples was performed as 
described previously [12]. For immunohistochemistry, 
the tissue samples were fixed in 4% buffered forma-
lin for 3–4 days and standard histologic preparation 
followed [13]. For the RNA and protein isolation, 
part of each sample was immediately stored in RNA- 
-later buffer (Ambion Inc., Austin, TX, USA) at 4°C 
overnight or immersed and kept in liquid nitrogen 
overnight; eventually all samples were stored at –80°C 
until further use. Total RNA Prep Plus kit (A & A 
Biotechnology, Gdynia, Poland) was used for RNA 
extraction according to manufacturer’s protocol and 
the obtained RNA was stored at –80°C. 1 µg RNA was 
reverse-transcribed (RT) with M-MuLV RT enzyme 
(Thermo Fisher Scientific, Fitchburg, WI, USA) and 
oligodT18 primers (Sigma-Aldrich, Munich, Germany) 
were added to obtain 20 µL of cDNA. The relative 
levels of p73a mRNA were assessed by quantitative 
real-time PCR (QPCR) method (StepOne apparatus, 
Life Technologies-Applied Biosystems, Grand Island, 
NY, USA). cDNA was 4× diluted and qPCR reaction 
was prepared in 10 µL final volume: 1 µL cDNA, 
200 nM each primer, 2× SensiFastSybr™ No-Rox kit 
(Bioline, London, UK). Primers were designed with 
the use of PrimerBlast online software: p73a: 5’-CAC-
CACGTTTGAGCACCTCTGG; 5’-TGCTCAG-
CAGATTGAACTGGGC, PGK1 (normalization 
gene): 5’-GTTGACCGAATCACCGACCTCTC; 
5’-AGAACAGAACATCCTTGCCCAGC. The 
qPCR time-temperature protocol was applied as 
previously described [13]. 
The semi-quantification of TAp73a protein was 
performed by Western-blot (WB) technique as pre-
viously described [14] with some modifications: we 
used rabbit polyclonal anti-TAp73a antibodies in 
1:1000 dilution in 2% TBS buffer (Sigma-Aldrich) 
and the overnight incubation at 4°C followed. After 
3× wash in TBS with 2% Tween (TBS-T) for 15 min, 
the incubation for 2 h was carried out with secondary 
anti-rabbit monoclonal horseradish peroxidase-con-
jugated antibodies (Sigma-Aldrich). TAp73a pro-
tein level was normalized to the level of GAPDH 
protein by using rabbit anti-GAPDH antibodies at 
1:5000 dilution.
The immunohistochemical (IHC) detection of TA-
p73a protein in CRC and normal colon wall sections 
was performed in paired samples of 9 CRC patients 
by previously described technique [15] using TP73a 
rabbit anti-human polyclonal antibody (bs-6147R, 
Bioss, Woburn, MA, USA) at the dilution 1:100. 
After incubation for 2 h with primary antibodies at 
room temperature, slides were washed in PBS and 
incubated with an appropriate secondary antibody 
[ImmPRESS Anti-Rabbit Ig (peroxidase) Polymer 
Detection Kit, Vector Labs, Burlingame, CA, USA] 
for 30 min. Immunoreactive cells were visualized by 
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addition of 3,3’-diaminobenzidine solution (DAB 
Peroxidase Substrate Kit, Vector Labs). The specific-
ity of the IHC staining was determined by a negative 
control, in which primary antibody was replaced by 
2.5% normal horse serum [ImmPRESS Anti-Rab-
bit Ig (peroxidase) Polymer Detection Kit] and the 
slides were processed under the same conditions as 
described.
Statistical analyses were performed using Prism 
ver. 6.05 program (GraphPad Software, San Diego, 
CA, USA) as described previously [13]. Mann-Whit-
ney U and Kruskal-Wallis ANOVA tests were applied 
to check the statistical significance between two or 
more groups of samples/patients, respectively. Spear-
man’s test was used to check the possible correlations. 
P < 0.05 was set as the level of statistical significance.
We found that the level of the p73a mRNA was 
by 37% lower in CRC neoplastically changed (tumor) 
samples than in unchanged mucosa and submucosa 
tissue obtained from the surgical margin (p = 0.041; 
Figure 1A). The lower p73a mRNA content was found 
in 15/23 (65%) patients. There were no differences 
between p73a mRNA level in tumor samples and 
age, gender, tumor location, UICC/AJCC, presence 
of metastasis or histological G grading; moreover, no 
correlations between molecular and clinical variables 
were found.
Interestingly, the semi-quantification of TAp73a 
protein by WB did not confirm the results of the 
p73a mRNA assessment since the lower and higher 
TAp73a protein contents were observed in 11/23 and 
12/23 of tumor samples, respectively, when compared 
with the median value of TAp73a protein in normal 
colon tissue (p = 0.61; data not shown). We did 
not find any correlation between p73a mRNA and 
TAp73a protein levels. In reference to CRC staging, 
no differences in TAp73a protein content and clin-
ical-pathological data were observed. However, in 
regard to histological G classification we found that 
TAp73a protein level was 5 times lower in poorly 
differentiated cancer cells (G3, n = 3) in comparison 
with moderately differentiated ones (G2, N = 20; 
p = 0.02; Figure 1B). 
The IHC analysis of TAp73a protein presence in 
CRC samples showed decreased immunoreactivity 
when compared with matched sections of the un-
changed colon wall in 4/9 patients, similar intensity 
of the IHC reaction in 4/9 patients and increased 
immunoreactivity in 1/9 patients. The TAp73a protein 
was localized mainly in the cytoplasm of the cancer 
cells. Moreover, the immunoreactive product was also 
present in the cytoplasm of epithelial cells and some 
stromal cells of the colon mucosa (Figure 2). 
The analysis of the p73 gene expression in CRC has 
been previously reported by other authors; however, 
with disparate results. Dominguez et al. [16] analyzed 
the expression of the N-terminal isoforms of p73 in 
tumor tissue of 113 CRC patients both at the mRNA 
and protein levels using QPCR and IHC method, 
respectively. They found increased levels of mRNAs 
encoding TAp73, aTAp73 as well as aNp73 isoforms 
in the tumor tissue compared with the macroscopically 
unchanged colon mucosa. TAp73 immunoreactivity 
was observed in 19% of the colon cancer cases, while 
TAp73 protein expression correlated with mRNA 
quantification in 22 (88%) of the 25 colon cases. Su et 
Figure 1. The expression of the p73 gene at the mRNA (A) and TAp73a protein (B) level in colorectal cancer (CRC) and 
matched normal colon mucosa (CRC control). mRNA levels were determined by real-time PCR and the TAp73a content 
by Western blotting as described in Material and methods. The results represent the mean value and standard deviation 
(SD). *Statistically significant difference between groups (p < 0.05), Mann-Whitney U test.
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al. analyzed TP73 gene expression at the mRNA and 
protein level in CRC by in situ hybridization and IHC 
technique [11] and found higher p73 mRNA and TP73 
protein levels in all samples of CRC neoplastically 
changed tissue than in paracancerous tissue. Guan 
et al. [17] investigated the expression of C-terminal 
TP73a protein isoforms by WB and both p73a and 
p73a by immunohistochemistry in tumor tissue and 
macroscopically unchanged colon tissue of 56 CRC 
patients. The p73 protein staining was confined to 
the nuclear area. Positive staining frequently showed 
a heterogeneous distribution and the intensity of 
staining also varied, whereas in our observations the 
staining intensities were similar (Figure 2). In normal 
colon mucosa 70% (39/56) cases were negative while 
CRC tissue demonstrated a high level of expression: 
73% (41/56) exhibited p73 characteristics (17). WB 
results showed that 82% (46/56) samples had high 
level of p73 protein expression, 14% (8/56) did not 
show a significant difference in p73 protein expression 
and 4% (2/56) of cases even expressed lower than 
the normal level of the control. The authors found 
positive correlation between the results of WB and 
IHC analyses [17]. 
The discrepancies between results of our study and 
those of other authors might have been caused by the 
differences in the applied methods, low number of the 
analyzed patients and diversity of the study group in 
terms of clinical and pathological features. Moreover, 
some disadvantage of our study may be connected 
with the different number of cases assessed by QPCR, 
WB and IHC methods. In fact, our study focused only 
on TAp73a isoform, which has pro-apoptotic function 
due to the presence of the TA domain. As a result, 
the TAp73a isoforms act intracellularly in the similar 
way as p53 protein [4]. Since other authors studied 
the whole group of TP73 isoforms [17] or the whole 
p73 mRNA without the isoform differentiation [11], 
our results may be only compared with the above 
mentioned data of Domininquez et al. [16].
Although other authors revealed opposite to our data 
of p73 gene expression between tumor and unchanged 
tissues of CRC patients, they also did not observe 
any associations between molecular and clinical and 
pathological parameters (such as sex, age or TNM 
status) [11, 16, 17]. On the contrary to our observa-
tions of decreased TAp73a protein in G3 samples, 
Su et al. [11] demonstrated overexpression of the p73 
Figure 2. Representative examples of p73 protein immunoreactivity in colorectal cancer and normal colon tissue. Weak 
immunoreactivity of the TAp73a protein in CRC tumor tissue (A) and strong expression in the corresponding normal 
mucosa of the same patient (B). Comparable intensity of the TAP73a protein immunoexpression in tumor tissue (C) and 
normal mucosa (D) of the same patient. The immunohistochemical staining was performed as described in the body text. 
Magnification: ×400.
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gene in CRC assessed as G2 and G3 compared with 
G1, both at the mRNA and protein levels. Again, such 
observation cannot be compared with our study, since 
none of our analyzed CRC sample was classified to 
G1 (well differentiated cells) grade.
In conclusion, our preliminary study confirms 
the observed contribution of the p73 gene to the 
progression of CRC; however, our results should 
be confirmed by larger number of cases with wider 
clinical-pathological spectrum.
Acknowledgements
The study was supported by grant of the Polish 
National Science Centre, No. N N402 683940.
References
1. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence 
and mortality worldwide: sources, methods and major patterns 
in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386. 
doi: 10.1002/ijc.29210.
2. Akkoca AN, Yanik S, Ozdemir ZT et al. TNM and Modified 
Dukes staging along with the demographic characteristics 
of patients with colorectal carcinoma. Int J Clin Exp Med. 
2014;7:2828–2835. PMID: 25356145.
3. Li XL, Zhou J, Chen ZR, Chng WJ. P53 mutations in colo-
rectal cancer — molecular pathogenesis and pharmacologi-
cal reactivation. World J Gastroenterol. 2015;21:84–93. doi: 
10.3748/wjg.v21.i1.84.
4. Jancalek R. The role of the TP73 gene and its transcripts 
in neuro-oncology. Br J Neurosurg. 2014;28:598–605. doi: 
10.3109/02688697.2014.908162.
5. Soldevilla B, Millan CS, Bonilla F, Dominguez G. The TP73 
complex network: ready for clinical translation in cancer? 
Genes Chromosomes Cancer. 2013;52:989–1006. doi: 10.1002/
gcc.22095.
6. Ferraiuolo M, Di Agostino S, Blandino G, Strano S. Oncoge-
nic intra-p53 family member interactions in human cancers. 
Front Oncol. 2016;6. doi: 10.3389/fonc.2016.00077.
7. Tissir F, Ravni A, Achouri Y, Riethmacher D, Meyer G, 
Goffinet AM. DeltaNp73 regulates neuronal survival in vivo. 
Proc Natl Acad Sci USA. 2009;106:16871–16876. doi: 10.1073/
pnas.0903191106.
8. Bahnassy AA, Zekri AR, Salem SE et al. Differential expres-
sion of p53 family proteins in colorectal adenomas and carci-
nomas: prognostic and predictive values. Histol Histopathol. 
2014;29:207–216. doi: 10.14670/HH-29.207.
9. Xu XL, Yu J, Zhang HY et al. Methylation profile of the pro-
moter CpG islands of 31 genes that may contribute to colorec-
tal carcinogenesis. World J Gastroenterol. 2004;10:3441–3454. 
doi: 10.3748/wjg.v10.i23.3441.
10. Sunahara M, Ichimiya S, Nimura Y et al. Mutational analysis 
of the p73 gene localized at chromosome 1p36.3 in colorectal 
carcinomas. Int J Oncol. 1998;13:319–323. PMID: 9664127.
11. Su XL, Ouyang XH, Yan MR, Liu GR. p73 expression and 
its clinical significance in colorectal cancer. Colorectal Dis. 
2009;11:960–963. doi: 10.1111/j.1463-1318.2008.01736.x.
12. Wierzbicki PM, Adrych K, Kartanowicz D et al. Underex-
pression of LATS1 TSG in colorectal cancer is associated 
with promoter hypermethylation. World J Gastroenterol. 
2013;19:4363–4373. doi: 10.3748/wjg.v19.i27.4363.
13. Klacz J, Wierzbicki PM, Wronska A et al. Decreased expres-
sion of RASSF1A tumor suppressor gene is associated with 
worse prognosis in clear cell renal cell carcinoma. Int J Oncol. 
2016;48:55–66. doi: 10.3892/ijo.2015.3251.
14. Wronska A, Lawniczak A, Wierzbicki PM, Kmiec Z. 
Age-related changes in sirtuin 7 expression in calorie-re-
stricted and refed rats. Gerontology. 2016;62:304–310. doi: 
10.1159/000441603.
15. Wierzbicki PM, Klacz J, Rybarczyk A et al. Identification of 
a suitable qPCR reference gene in metastatic clear cell re-
nal cell carcinoma. Tumor Biol. 2014;35:12473–12487. doi: 
10.1007/s13277-014-2566-9.
16. Dominguez G, Garcia JM, Pena C et al. DTAp73 upregulation 
correlates with poor prognosis in human tumors: putative in 
vivo network involving p73 isoforms, p53, and E2F-1. J Clin 
Oncol. 2006;24:805–815. doi: 10.1200/JCO.2005.02.2350.
17. Guan M, Peng HX, Yu B, Lu Y. p73 overexpression and an-
giogenesis in human colorectal carcinoma. Jpn J Clin Oncol. 
2003;33:215–220. doi: 10.1093/jjco/hyg045.
Submitted: 29 July, 2016 
Accepted after reviews: 17 August, 2016 
Available as AoP: 19 August, 2016
